[1] BONI C,BARILI V,ACERBI G,et al. HBV immune-therapy:From molecular mechanisms to clinical applications[J]. Int J Mol Sci,2019,20(11):2754.
|
[2] TANG J,WU ZY,DAI RJ,et al. Hepatitis B virus-persistent infection and innate immunity defect:Cell-related or virusrelated?[J]. World J Clin Cases,2018,6(9):233-241.
|
[3] RUAN B,YU Z,YANG S,et al. Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China[J]. BMC Infect Dis,2019,19(1):617.
|
[4] BERTOLETTI A,KENNEDY P. HBV antiviral immunity:Not all CD8 T cells are born equal[J]. Gut,2019,68(5):770-773.
|
[5] Chinese Society of Infetious Disease,Chinese Society of Hepatology,Chinese Medical Association. The expert consensus on functional cure of chronic hepatitis B[J]. J Clin Hepatol,2019,35(8):1693-1701.(in Chinese)中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎临床治愈(功能性治愈)专家共识[J].临床肝胆病杂志,2019,35(8):1693-1701.
|
[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
[7] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
|
[8] SUSLOV A,WIELAND S,MENNE S. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B[J]. Curr Opin Virol,2018,30:9-17.
|
[9] YANG Y,HAN Q,ZHANG C,et al. Hepatitis B virus antigens impair NK cell function[J]. Int Immunopharmacol,2016,38:291-297.
|
[10] SALIMZADEH L,LE BERT N,DUTERTRE CA,et al. PD-1blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection[J]. J Clin Invest,2018,128(10):4573-4587.
|
[11] MIAO J,YUAN CY,LI QW,et al. An analysis on correlations between expressions of CD4+and CD8+T lymphocytes in peripheral blood and quantitative level of HBsAg in patients with chronic hepatitis B virus infection[J]. Chin J TCM WM Crit Care,2016,23(4):399-403.(in Chinese)苗静,袁晨翼,李秋伟,等.慢性乙型肝炎病毒感染患者外周血CD4+、CD8+T细胞的表达与HBsAg定量的相关性分析[J].中国中西医结合急救杂志,2016,23(4):399-403.
|
[12] RIAZALHOSSEINI B,MOHAMED Z,APALASAMY YD,et al.Association between microRNA-196A2 and microRNA-146A polymorphisms and progression to cirrhosis and hepatocellular carcinoma in patients with viral hepatitis B[J]. Pharmacogenet Genomics,2016,26(2):74-79.
|
[13] LI CD,CHEN XL,DUAN ZJ,et al. Determination of proportions of T cell subsets and levels of interleukin-15 and interleukin-16 in peripheral blood of patients with chronic hepatitis B virus infection and correlation between them[J]. J Clin Hepatol,2015,31(11):1857-1861.(in Chinese)李彩东,陈锡莲,段正军,等.慢性HBV感染者外周血T淋巴细胞亚群的变化及其与白细胞介素15、白细胞介素16的相关性分析[J].临床肝胆病杂志,2015,31(11):1857-1861.
|
[14] SUN KK,HUANG CH,WANG YY,et al. Detection of T lymphocyte surface costimulatory molecules and T lymphocyte subsets in peripheral blood of HBV infected patients and its clinical significance[J]. Chin J Clin Pharmacol Ther,2019,24(3):241-247.(in Chinese)孙凯凯,黄春红,王云云,等.HBV感染者外周血T淋巴细胞表面共刺激分子和T淋巴细胞亚群的检测及临床意义[J].中国临床药理学与治疗学,2019,24(3):241-247.
|
[15] CORTI D,LANZAVECCHIA A. Broadly neutralizing antiviral antibodies[J]. Annu Rev Immunol,2013,31(1):705-742.
|
[16] PEPPA D,GILL US,REYNOLDS G,et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cellmediated deletion[J]. J Exp Med,2013,210(1):99-114.
|
[17] LIU EH,LIU CM. Quantitative changes of peripheral blood lymphocyte subsets and HBV DNA in patients with chronic HBV infection under different pathological conditions[J]. J Baotou Med Coll,2018,34(10):13-15.(in Chinese)刘恩惠,刘传苗.慢性HBV感染者不同病理状态下外周血淋巴细胞亚群及HBV DNA定量变化[J].包头医学院学报,2018,34(10):13-15.
|
[18] LIU X,HE L,HAN J,et al. Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer[J]. PLo S One,2017,12(2):e0170605.
|
[19] WANG Y,HUANG YY,MA Y,et al. Expression features of follicular helper T cells in peripheral blood in patients with chronic hepatitis B[J]. J Clin Hepatol,2018,34(1):58-62.(in Chinese)王燕,黄友英,马燕,等.慢性乙型肝炎患者外周血中滤泡辅助性T淋巴细胞的表达特征[J].临床肝胆病杂志,2018,34(1):58-62.
|
[20] YANG C,LI N,WANG Y,et al. Serum levels of B-cell activating factor in chronic hepatitis B virus infection:Association with clinical diseases[J]. J Interferon Cytokine Res,2014,34(10):787-794.
|
[21] SHI J,ZHAO J,ZHANG X,et al. Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-β-dependent emperipolesis in HBV cirrhotic patients[J]. Sci Rep,2017,7:44544.
|